Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 687 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR Coping with COVID: New Stimulus Funds and Unemployment Benefit Update January 5, 2021 ESMO Launches Its Roadmap 2030 to Support Oncology Professionals and Foster... February 4, 2026 EMA Recommends a Change to the Terms of the Marketing Authorisation... October 23, 2025 Why do non-smokers face delays in getting a lung cancer diagnosis? November 25, 2022 Load more HOT NEWS Easy Meals at Home News digest – skin cancer deaths, Public Health England plans and... Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of... ctDNA Analysis is Feasible for Detection of Minimal Residual Disease After...
